Współczesna terapia autoimmunizacyjnej choroby ucha wewnętrznego

• Authors: Waldemar Narożny , Ivan Kocić

Title variants

EN

Current therapy of autoimmune inner ear disease

• Languages of publication: PL EN

Abstracts

PL

Autorzy dokonali przeglądu najnowszego piśmiennictwa dotyczącego autoimmunizacyjnej choroby ucha wewnętrznego (AIED), przedstawiając m.in. epidemiologię, obraz kliniczny, współczesną diagnostykę laboratoryjną, sposoby rozpoznawania i leczenia tej choroby. Szczególną uwagę autorzy poświęcili wzrastającym możliwościom współczesnej terapii AIED, w tym m.in. wielokierunkowej farmakoterapii (sterydy, leki immunosupresyjne, blokery cytokin) oraz plazmaferezy.

EN

The authors have presented an overview of the latest literature on autoimmune inner ear disease (AIED), presenting, among other things, epidemiology, clinical picture, contemporary laboratory diagnostics, methods of recognition and treatment of this disease. Particular attention has been paid by the authors to the increasing possibilities of the contemporary therapy of AIED, including among others, multidirectional pharmacotherapy (steroids, immunosupressive drugs, anti-cytokine drugs) and plasmapheresis.

Keywords

EN

blokery TNF-α; choroba autoimmunizacyjna uchawewnętrznego; plazmafereza; sterydy; współczesna terapia

Discipline

• MEDICINE: MEDICINE

• Publisher: Mediton
• Journal: Otorynolaryngologia - przegląd kliniczny
• Year: 2017
• Volume: 16
• Issue: 1
• Pages: 1-8

Contributors

author

Waldemar Narożny

• Katedra i Klinika Otolaryngologii, Gdański Uniwersytet Medyczny, Gdańsk

author

Ivan Kocić

• Katedra i Zakład Farmakologii, Gdański Uniwersytet Medyczny, Gdańsk

References

• 1. Woolf N, Harris J, Ryan A, Butler DM, Richman DD. Hearing loss in experimental cytomegalovirus infection of the guinea pig inner ear – prevention by systemic immunity. Ann Otol Rhinol Laryngol 1985; 94: 350-6.
• 2. Buniel MC, Geelan-Hansen K, Weber PC, Tuohy VK. Immunosupressive therapy for autoimmune inner ear disease. Immunotherapy 2009; 1(3): 425-34.
• 3. Goodall AF, Siddiq MA. Current understanding of the pathogenesis of autoimmune inner ear disease: a review. Clin Otolaryngol 2015; 40: 412-19.
• 4. Yoo TJ, Yazawa Y. Immunology of cochlear and vestibular disorders. (w) Textbook of audiology medicine. Clinical aspects of hearing and balance. Luxton L, Furman JM, Martini A, Stephens D (red.). Martin Dunitz Taylor & Francis Group 2003: 61-87.
• 5. McCabe B. Autoimmune sensorineural hearing loss. Ann Otol 1979; 88: 585-9.
• 6. Ruckenstein MJ. Autoimmune inner ear disease. Curr Opin Otolaryngol Head Heck Surg 2004; 12: 426-30.
• 7. Śliwińska-Kowalska M. Choroby ucha wewnętrznego o podłożu immunologicznym. (w) Audiologia kliniczna. Śliwińska-Kowalska M (red.). Mediton, Łódź 2005: 271-80.
• 8. Śliwińska-Kowalska M. Immunologia i immunopatologia ucha wewnętrznego. (w) Audiologia kliniczna. ŚliwińskaKowalska M (red.). Mediton, Łódź 2005: 79-84.
• 9. Hain TC. Autoimmune inner ear disease (AIED). http:// www.dizziness-and-balance.com/disorders/autoimmune/ aied.html [04.08.2017].
• 10. Harris JP, Surgeon S. Choroby ucha wewnętrznego o podłożu immunologicznym. Otorynolaryngologia 2007; 6(4): 163-78.
• 11. Hirose K, Wener MH, Duckert LG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope 1999; 109: 1749-54.
• 12. Moscicki RA, San Martin JE, Quintero CH, Rauch SD, Nadol JB, Bloch KJ. Serum antibody to inner ear proteins in patients with progressive hearing loss. JAMA 1994; 272: 611-16.
• 13. Gottschlich S, Billing PB, Keithley EM, Weisman MH, Harris JP. Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Ménière’s disease. Laryngoscope 1995; 105: 1347-52.
• 14. Yeom K, Gray J, Nair TS, Arts HA, Telian SA, Disher MJ, El-Kashlan H, Sataloff RT, Fisher SG, Carey TE. Antibodies to HSP-70 in normal donors and autoimmune hearing loss patients. Laryngoscope 2003; 113: 1770-6.
• 15. García Berrocal JR, Ramírez-Camacho R, Vargas JA, Millan I. Does the serological testing really play a role in the diagnosis immune-mediated inner ear disease? Acta Otolaryngol (Stockh) 2002; 122: 243-8.
• 16. Zeitoun H, Beckman JG, Arts HA, Lansford CD, Lee DS, El-Kashlan AK, et al. Corticosteroids response and supporting cell antibody in autoimmune hearing loss. Arch Otolaryngol Head Neck Surg 2005; 131: 665-72.
• 17. Baruah P. Cochlin in autoimmune inner ear disease: is the search for an inner ear autoantigen over? Auris Nasus Larynx 2014; 41: 499-501.
• 18. Śliwińska-Kowalska M. Choroby ucha wewnętrznego o podłożu immunologicznym. Biblioteczka Prospera Meniere’a. Kangur, Warszawa 2001, 5(1): 7-32.
• 19. Brant JA, Eliades SJ, Ruckenstein MJ. Systematic review of treatments for autoimmune inner ear disease. Otol Neurotol 2015; 36: 1585-92.
• 20. Harris JP, Weisman MH, Derebery JM, Harris JP. Treatment of corticosteroid – responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003; 290: 1875-83.
• 21. Sismanis A, Thomson T, Willis HE. Methotrexate therapy for immune hearing loss: a preliminary report. Laryngoscope 1994; 104: 932-4.
• 22. Parnes L, Sun A, Freeman D. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999; 109: 1-17.
• 23. Yang GS, Song HT, Keithley EM, Harris JP. Intratympanic immunosuppressive for prevention of immune – mediated sensorineural hearing loss. Am J Otol 2000; 21: 499-504.
• 24. Moscicki RA. Immune-mediated inner ear disorders. (w) Baloh RW (red.). Balliere’s Clinical Neurology. Bailliere Tindall. London 1994; 3: 547-63.
• 25. Saraçaydin A, Katircioglu S, Karatay MC. Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease. J Int Med Res 1993; 21: 192-6.
• 26. Heywood RL, Hadavi S, Donnely S, Patel N. Infliximab for autoimmune inner ear disease: case report and literature review. J Laryngol Otol 2013; 15: 1-3.
• 27. Gopen Q, Keithley EM, Harris JP. Mechanisms underlying autoimmune inner era disease. Drug Discovery Today: disease mechanism 2006; 3(1): 137-42.
• 28. Ma C, Billings P, Harris JP, Keithley EM. Characterization of an experimentally induced inner ear immune response. Laryngoscope 2000; 110: 451-6.
• 29. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Tumor necrosis factor-α, an initiator and etanercept, an inhibitor of cochlear inflammation. Laryngoscope 2002; 112: 1627-34.
• 30. Wang X, Truong T, Billings PB, Harris JP, Keithley EM. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol 2003; 24: 52-7.
• 31. Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo – controlled study. Otol Neurotol 2005; 26: 903-7.
• 32. Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, Rahman MU. Etanercept therapy for immune-mediated cochleovestibular disorders: a multicenter, open-label, pilot study. Arthritis Rheum 2005; 53: 337-42.
• 33. Van Wijk FV, Staecker H, Keithley E, Lefebvre PP. Local perfusion of the Tumor Necrosis Factor α blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurotol 2006; 11: 357-65.
• 34. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in pilot study. Otol Neurotol 2001; 22: 619-24.
• 35. Vambutas A, Lesser M, Mullooly V, Pathak S, Zahtz G, Rosen L, Goldofsky E. Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J Clin Invest 2014; 124: 415-22.
• 36. Matteson EL, Tirzman O, Facer GW et al. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 2000; 109: 710-14.
• 37. Salley LH Jr, Grimm M, Sismanis A, Spencer RF, Wise CM. Methotrexate in the management of immune mediated cochleovestibular disorders: clinical experience with 53 patients. J Rheumatol 2001; 28: 1037-40.
• 38. Matteson EL, Fabry DA, Facer GW, Beatty CW, Driscoll CL, Strome SE, McDonald TJ. Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis Rheum 2001; 45: 146-50.
• 39. Derebery MJ, Fisher LM, Voelker CCJ, Calzada A. An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. Otol Neurotol 2014; 35: 1515-21.
• 40. Mora R, Jankowska B, Passali GC, Mora F, Passali FM, Crippa B, Quaranta N, Barbieri M. Sodium enoxaparin treatment of sensorineural hearing loss: an immunemediated response?. Int Tinnitus J 2005; 11: 38-42.
• 41. Cohen S, Roland P, Shoup A, Lowenstein M, Silverstein H, Kavanaugh A, Harris J. A pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol 2011; 16: 214-21.
• 42. Luetje CM, Berliner KI. Plasmapheresis in autoimmune inner ear disease: long-term follow-up. Am J Otol 1997; 18: 572-6.
• 43. Hussain NS, Rumbaugh J, Kerr D, Nath A, Hillis AE. Effects of prednisone and plasma exchange on cognitive impairment in Hashimoto encephalopathy. Neurology 2005; 64: 165-6.

• Document Type: article